Jan. 9 at 1:13 PM
$ELDN Anticipated 2026 Milestones Present 24-month data from eight patients in Phase 1 extension study evaluating tegoprubart in kidney transplantation at the American Society of Transplant Surgeons (ASTS) Winter Symposium in Phoenix, AZ. Details are below: Title : Long-Term Outcomes of a Phase 1, Single Arm Cohort of De Novo Kidney Transplant Recipients Treated with Tegoprubart, an Anti-CD40L Antibody, as the Core Immunosuppression Regimen Abstract ID: #44 Session Title : Poster Session B Date : Friday, January 23, 2026, from 5:45 - 7:15 p.m.
